Wani majiyyaci mai fama da cutar kansar kwakwalwa, wanda ya sake kamuwa bayan jiyya 17 na CAR-T, ya ga ciwon kansa ya ɓace gaba ɗaya cikin makonni 4 bayan an ba shi sabuwar maganin TIL kuma ya kasance ba shi da ƙari tsawon sama da watanni 20.
Don tambayoyi game da sabbin hanyoyin magance cutar kansa da gwaje-gwajen asibiti:
Waya: 4008803716 | WeChat: 17801183037| Email ：100085_010@163.com
An gano wani majiyyaci namiji mai shekaru 56 yana da glioblastoma na gaba na hagu (IDH wild-type, WHO Grade 4, EGFR amplification) - ɗaya daga cikin nau'in glioma na kwakwalwa mafi muni da wahalar magani.
Bayan an yi masa tiyatar cire ƙari a ranar 5 ga Janairu, 2023, da farko an yi masa magani na yau da kullun, amma yanayinsa ya sake dawowa bayan ɗan lokaci na kwanciyar hankali. Daga baya, an yi masa jimillar magunguna 17 na CAR-T waɗanda ke da nufin magance ƙwayoyin cuta guda biyu daban-daban, duk da haka cutar ta ci gaba da ci gaba.
Cikin matsananciyar damuwa, ya shiga wani gwaji na asibiti don sabon maganin TIL. Sakamakon ya kasance abin mamaki: makonni 4 kacal bayan shigar da ƙwayoyin TIL, gwaje-gwajen hoto sun nuna cewa an kawar da ciwon da ke cikin kwakwalwarsa gaba ɗaya, inda aka sami cikakken amsa, kuma ya kasance ba shi da ciwon daji tsawon sama da watanni 20.
—
Fafawa Don Tsira A Cikin Matsanancin Hali
Ana kiran Glioblastoma a matsayin "mai kisan kai na farko a cikin kwakwalwa." Lokacin da aka gano cutar yana jin kamar farkon ƙidayar rayuwa.
Bayan an gano cutar da Mr. W ya yi, an fara yi masa tiyatar cire ciwon kwakwalwa mai hatsari, sannan aka yi masa maganin chemotherapy da radiotherapy na temozolomide. Duk da haka, ba a shawo kan matsalarsa ba.
Daga baya, ya gwada magunguna daban-daban guda biyu na CAR-T da ke kai hari ga ƙwayoyin cuta daban-daban, inda ya karɓi allurai sama da 10 a cikin tumbi gaba ɗaya, amma wannan bai dakatar da ci gaban ƙari ba.
Magungunan gargajiya suna da iyakataccen tasiri ga ci gaban glioma na kwakwalwa. Ko da tare da shirye-shiryen magani da suka haɗa da tiyata, radiotherapy, da chemotherapy, matsakaicin rayuwa ga marasa lafiya yana kusan watanni 14.6 ne kawai.
Suna fuskantar irin wannan yanayi na rashin bege, Mista W da iyalinsa sun ji matsananciyar baƙin ciki har sai da suka ji labarin gwajin asibiti na maganin TIL.
Maganin TIL
Maganin TIL, ko kuma maganin lymphocyte mai toshewar tumor, wani sabon tsarin rigakafi ne na ƙwayoyin halitta.
Wannan maganin yana farawa ne da sabon ƙwayar ciwon daji na majiyyaci a matsayin kayan aiki. Bayan ware, gyara, da faɗaɗawa a cikin vitro, ana sake haɗa ƙwayoyin cikin majiyyaci, ana samun ingantaccen magani wanda ke "yaƙi da ciwon da kansa."
Ba kamar maganin gargajiya na CAR-T ba, maganin GC101 TIL baya buƙatar lymphdepletion ko allurar IL-2, wanda hakan yana inganta aminci da sauƙin magani sosai.
An ƙirƙiro maganin TIL na GC101 ta Juncell Therapeutics, kuma shine maganin TIL na farko a duniya wanda ba ya buƙatar lymphdepletion ko allurar IL-2, ta hanyar amfani da dandamalin faɗaɗa ƙwayoyin halitta na DeepTIL® da kansa.
Bayanan asibiti da ke akwai sun nuna cewa GC101 yana da saurin amsawar da ta wuce kashi 35% idan aka kwatanta da nau'ikan ciwon daji daban-daban. Marasa lafiya da yawa sun sami cikakken kawar da ciwon daji da kuma cikakken amsawa, tare da tsawon lokacin da ba a taɓa samun ciwon daji ba wanda ya wuce shekaru 3.
Tsarin Magani
A ƙarshen shekarar 2023, Mista W ya yi nasarar shiga gwajin asibiti na GC101 TIL.
Ƙungiyar likitocin ta yi amfani da ƙwayoyin TIL da aka haɓaka daga samfurin tiyatar da aka samu shekara guda da ta gabata, wanda aka adana har sai an buƙata.
Ƙungiyar jiyya ta yi nasarar faɗaɗa ƙwayoyin zuwa jimillar ƙwayoyin TIL 2.95 × 10^10, inda ƙwayoyin T ke ɗauke da kashi 99.92% na yawan jama'a, galibi ƙwayoyin T na CD8⁺ (97.85%).
Bayan an yi masa kwaskwarima, Mr. W ya karɓi maganin TIL cell a ranar 12 ga Disamba, 2023.
A lokacin allurar, Mr. W bai sami wani mummunan sakamako ba, sai dai ƙaramin zazzabi wanda ya ragu da sauri. Idan aka kwatanta da magungunan TIL na gargajiya, wannan sigar da aka gyara ta nuna aminci mafi girma.
Juyawa Mai Ban Mamaki
Makonni 4 kacal bayan an yi wa TIL cell allura, gwaje-gwajen hoto a ranar 8 ga Janairu, 2024, sun nuna cewa an kawar da ciwon da ke cikin kwakwalwar Mr. W gaba ɗaya.
Mafi mahimmanci, har zuwa watan Oktoba na 2025, majiyyacin ya ci gaba da rayuwa ba tare da ƙari ba tsawon sama da shekaru 1.8 (wanda aka ƙididdige a lokacin da aka fitar da labarai, wannan ya wuce watanni 20), ya sake samun rayuwa ta yau da kullun.
Wannan shari'ar ta kafa sabon tarihin rayuwa ga glioblastoma mai sake dawowa kuma tana ba da muhimmiyar shaida ta asibiti don dabarun maganin "samun samfuran nama da wuri, sake haɗa TIL bayan sake dawowa."
Za a gabatar da wannan gagarumin nasara a cikin wani fosta a taron shekara-shekara na 40 na Ƙungiyar Kula da Kamuwa da Cutar Kansa, wanda zai gudana daga 7-9 ga Nuwamba, 2025, inda za a nuna shi ga ƙwararrun masana'antu na duniya.
Masu Ra'ayin Gaba
Maganin TIL ya nuna yuwuwar ba kawai a cikin maganin glioma na kwakwalwa ba, har ma ya nuna inganci mai ban mamaki akan wasu ciwace-ciwacen da suka yi ƙarfi kamar ci gaban melanoma da ciwon huhu na ƙwayoyin halitta marasa ƙarami.
A watan Fabrairun 2024, maganin ƙwayoyin TIL na farko a duniya, Lifileucel, ya sami amincewar FDA a Amurka don kula da marasa lafiya da ke fama da cutar melanoma mai tsanani waɗanda suka taɓa samun maganin hana PD-1.
A lokaci guda kuma, kasar Sin tana ci gaba da bunkasa binciken asibiti kan maganin TIL. Cibiyar Nazarin Magunguna ta Hukumar Kayayyakin Lafiya ta Kasa ta amince da babban gwajin asibiti na Mataki na II na allurar GC101 TIL ta Juncell Therapeutics da ke kan gaba wajen magance cutar melanoma.
Bugu da ƙari, a ranar 14 ga Oktoba, 2024, an fara gwajin farko na yin rijistar magungunan ƙwayoyin TIL na China musamman don cutar kansar huhu a hukumance, wanda aka yi niyya don magance cutar kansar huhu mai ci gaba ba ƙaramin ƙwayar halitta ba.
—
A halin yanzu, har yanzu akwai gwaje-gwaje da dama na asibiti don sabbin magungunan hana cutar kansa da fasahohi a China da ke neman marasa lafiya.
Sashen ƙasa da ƙasa na Asibitin Oncology na Yankin Kudu na Beijing yana ba da shawarwari kan sabbin magunguna da fasahohi.
Lambar Waya: 4008803716
Shaidar WeChat: 17801183037
Email ①: 100085_010@163.com
Email ②: myimmnet@163.com
Lokacin Saƙo: Nuwamba-20-2025